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T HIRTEEN years ago this month, liver 
replacement with extended patient sur-
vival was accomplished for the first time. 
That little recipient lived for more than a year 
before dying of metastases from the hepa-
toma for which she originally had been 
treated. I 
RESULTS WITH CONVENTIONAL 
IMMUNOSUPPRESSION 
The demonstration of its feasibility did not 
make orthotopic liver transplantation a 
widely used clinical procedure, and in fact, 
only we2 and CaIne and Williams of England3 
have persisted in large scale trials. Two years 
ago in Rome, we summarized our experience 
and that of the British group using conven-
tional immunosuppression with azathioprine 
and prednisone, to which in the Colorado 
series we had added lymphoid depletion with 
antilymphocyte globulin (ALG) or, more 
recently, thoracic duct drainage. 
Our results have been so thoroughly 
reported that I will dwell on them in summary 
only, and then mainly to emphasize how 
unsatisfactory they have been. By early 
summer of 1976, we had treated 111 consecu-
tive patients. Thirty-one (28%) of these recip-
ients had survived for at least a year (Fig. 1). 
Now, with follow-ups of 4.5-10.5 years, 13 
patients are still living. The flatness of the late 
life survival curve has been an important 
stimulus to persist in these efforts, and so has 
the very acceptable quality of life of these 
chronic survivors. Chronic graft rejection has 
been the single most common cause of late 
death.2 
A second Colorado series of 30 patients was 
compiled in the subsequent 18 months, ending 
in early 1978. Half (50%) of these patients 
survived for at least 1 year, and today, after 
2.5 to almost 4 years, 13 (43%) are still living 
(Fig. 1). It was thought that improvements in 
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surgical technique (especially biliary tract 
reconstruction), better diagnosis of pos topera-
tive hepatic dysfunction, and refinements in 
immunosuppression were responsible for the 
better results. 
It is distressing to report that we were 
unable to maintain these gains in a further 
series of 30 patients, of whom the first 23 
have been documented elsewhere.4 Instead of 
using ALG, many of these last 30 patients 
had lymphoid depletion with thoracic duct 
drainage4 or lymphaphoresis. All 30 were 
given azathioprine and prednisone. The 
projected I-year survival is only 33% (Fig. 1). 
Many of the early deaths in the last series 
were attributable to technical or management 
errors, as in the past. These misadventures 
often were not intrinsically lethal but became 
so because of the need for high-dose steroid 
therapy. 
The preoperative use of thoracic duct 
drainage (TDD) as a steroid-sparing device 
which had been shown to be valuable in 
cadaveric kidney transplantationS proved im-
practical for conditioning of liver recipients.4 
The amount of thoracic duct lymph drained 
in patients with chronic liver disease was 
always large and sometimes it was prodigious. 
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Fig. 1. Life survival curves of three successive 
series of patients who were given orthotopic liver 
homografts at the University of Colorado. 
In Fig. 2 is shown a progressive increase in the 
volume of thoracic duct lymph, which rose to 
nearly a liter an hour during the 2 weeks 
preceding transplantation at the same time as 
the cell yield fell. After successful transplan-
tation, the lymph volumes were halved (Fig. 
2). This patient had a good result, but two 
patients died during preparation for trans-
plantation because of our inability to manage 
fluid exchange of as much as 2Iiters/hr. 
THE JUSTIFICATION FOR CHANGE 
By the end of 1979, we had concluded that 
no real movement of liver transplantation 
toward an acceptable risk was going to be 
possible without a drastic change in immuno-
suppressive techniques. Thus, when the possi-
bility arose of using cyclosporin-A, we had no 
hesitation in proceeding. As everyone here 
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Fig. 2. Daily lymph volumes and lymphocytes 
obtained by TOO in an orthotopic liver recipient whose 
original hepatic disease was primary biliary cirrhosis. 
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knows, cyclosporin-A was the product of a 
Sandoz Corporation research team. The 
powerful immunosuppressive qualities of cy-
closporin-A were accurately delineated in 
rodents by Borel et al. 6 Caine and his asso-
ciates of Cambridge, who were the first to use 
cyclosporin-A in larger animals and humans, 
reported these trials to this Society in Rome 
almost 2 years ago.7 In Caine's most recent 
comprehensive publication,8 he described the 
administration of cyclosporin-A to two liver 
recipients, of whom both were then alive with 
follow-ups of a few weeks. By personal 
communication 2 weeks ago, the number of 
cyclosporin-A liver cases in Cambridge had 
increased to five. Three were still alive (lon-
gest follow-up lO months), although one of 
the three had been switched to azathioprine-
prednisone because of nephrotoxicity. The 
deaths were due to rejection in one instance 
and an unexplained cardiac arrest 3 weeks 
postoperatively in the other. 
CYCLOSPORIN-A AND RENAL 
TRANSPLANTATION IN COLORADO 
When cyclosporin-A became available for 
clinical trials in the United States in late 
1979, we began its evaluation in the simple 
kidney transplant model. From the beginning, 
it was obvious that unless some hidden prob-
lem surfaced, cyclosporin-A would change the 
face of transplantation. Between December 
1979 and 1 month ago, we treated 36 recip-
ients of 37 cadaveric kidneys with cyclospo-
rin-A and prednisone. Eleven of the patients 
also had preoperative lymphoid depletion 
with thoracic duct drainage (10 examples) or 
lymphaphoresis (1 example}.9 After 1-6.5 
months, 89% of the patients have been liber-
ated from dialysis (Table 1). Two patients 
died with well functioning kidneys, for a 
mortality of 5.6%. Two kidneys were lost to 
rejection, and a third organ was removed 
because of ureteral necrosis. Even though the 
follow-ups are still short, the early results 
(Ta ble 1) have been superior to those 
achieved by us in the past with any other kind 
of immunosuppression, particularly consider-
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Table 1. Cadaveric Renal Transplantation at the University of Colorado Under Cyclosporin-A and Steroid Therapy 
(Eleven of the 36 Patients Also had Preoperative lymphoid Depletion 
With Thoracic Duct Drainage or lymphapheresis) 
Primary transplantation 
Retransplantation 
Total 
Patients 
30 
6 
36 
Grafts Deaths· 
30 2 
7 0 
37 2 (5.6%) 
Patients 
Kidneys Lost off 
Other Than Death Dialysis 
1 t 27 (90%) 
2t 5 (83%) 
3 32 (89%) 
·One death from pneumonitis; one death from complication of coronary artery bypass. 
tloss from rejection. 
tOne loss from ureteral necrosis, the other from rejection. 
ing the fact that retranspiantations were 
included in the statistics. 
Thus, we reinforce Caine's optimistic 
projections about the future role of cyclospo-
rin-A in transplantation. However, our views 
about how to best use this valuable agent9 are 
divergent from those of the Cambridge team, 
which has warned against combining cyclo-
sporin-A with other agents. In constrast, we 
have concluded that cyclosporin-A alone, 
even in doses of 15-20 mg/kg/day, does not 
consistently prevent rejection, that it should 
be combined with steroid therapy for optimal 
use, and that the proper amount of prednisone 
when cyclosporin-A is used is much smaller 
than when steroids are combined with 
azathioprine. Finally, cyclosporin-A has been 
safely combined with thoracic duct drainage. 
Conceptually, we have substituted cyclo-
sporin-A for azathioprine in what is a 
modern-day version of the time-honored 
double-drug immunosuppression introduced 
in 1962 and 1963.10 Having learned that 
rejection usually can be expected, we now 
start the steroids on the day of operation and 
reduce the prednisone in adults by 20 or 40 
mg/day until a maintenance dose of 20 mg/ 
day is reached (usually within 5 or 6 days). 
The amount of prednisone needed in the first 
3 months has been between one-fifth and 
one-tenth that which we used to give when 
prednisone was combined with azathioprine. 
Besides learning from kidney recipients 
how to provide immunosuppression, this expe-
rience gave insight into the hepatotoxicity 
that has been seen with cyclosporin-A. We 
have seen significant hepatotoxicity, includ-
ing jaundice in J 5% of our kidney recipients, 
always with daily cyclosporin-A doses of 
about 17.5 mg/kg.9 This information in 
kidney graft recipients has been important in 
making decisions about how to give cycIospo-
rin-A in liver transplant recipients. The 
patient whose coursc is shown in Fig. 3 devel-
oped jaundice 4 weeks after renal transplan-
tation, while being given 17.5 mg/kg/day of 
cyclosporin-A. The hepatic dysfunction 
promptly reversed when the cyc\osporin was 
reduced to 7.3 mg/kg/ day. At the new low 
dose of cyc\osporin-A, the kidney graft began 
to reject, requiring an adjustment of steroids. 
After weeks of drug juggling, a good result 
was obtained. 
o h100 ~bOMM~~~ __ ~~ __ ~-f~~~ __ ~~ __ ~_ 
MP=1g METHYLPREDNISOLONE + WEEKS, POST TRANSPLANT 
Fig. 3. The development of jaundice in the recip-
ient of a cadaveric kidney who was being treated with 
cyclosporin-A. Note decline of the bilirubin after reduc-
tion of the cyclosporin-A dose, but with the penalty of 
renal homograft rejection. Eventually, the combination 
of prednisone plus an increased dose of cyclosporin-A 
allowed control of the rejection. 
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Table 2. Orthotopic Liver Transplantation at the University of Colorado Under 
Cyclosporin-A and Steroid Therapy 
"- ---,,-- ,-"------_. 
mg/dl mg/kg/Day mg/Day 
OT Age Lymphoid Date of Bilirubin Cyclosporin-A Prednisone 
No. (Years) Diagnosis Depletion Operation Outcome 7/1/80 7/1/80 7/1/80 
171 29 Chronic aggressive hepatitis 2 month, TOO 3/9/80 Alive 1.2 12 20 
172 24 Hepatoma No 3/10/80 Alive 4.0 10 25 
173 34 Secondary biliary cirrhosis 1.5 month 
Lymphapheresis 3/21/80 Alive 0.6 11 20 
174 20 Budd-Chiari syndrome No 3/25/80 Alive 0.6 8 10 
175 41 Primary biliary cirrhosis No 4/13/80 Alive 1.8 10 15 
176 33 Sclerosing cholangitis No 5/13/80 Alive 3.0 10.5 20 
177 26 Chronic aggressive hepatitis No 5/17/80 Alive 2.0 10 20 
178 37 Secondary biliary cirrhosis No 5/30/80 Operative death 
179 23 Budd-Chiari syndrome No 
CYCLOSPORIN-A AND LIVER 
TRANSPLANTATION 
6/5/80 
The first liver transplantation under cyclo-
sporin-A was not attempted until experience 
had been acquired with 22 cadaveric kidney 
graftings. Since then, nine orthotopic liver 
transplantations have been performed (Table 
2). There was one operative death, when the 
abdominal incision could not be closed despite 
repeated attempts during a 48 hr period. 
Postoperative therapy with cyclosporin-A was 
not provided. Of the eight survivors, all are 
being treated with cyclosporin-A. One has 
serious residual neurologic injury from a 
DENVER SERIES 
LIVER TRANSPLANT, CVCLOSPORIN-A OT 176<;> 
CREATININE 
(mQ%) 
ALKALINE PHOSPHATASE 
(I.u.) 
BILIRUBIN 
(total, mQ%) 
PREDNISONE 
(mQ/doy) 
CYCLOSPORIN-A 
(mg/kQ Iday) 
5 
4 
T. 
.. 
Alive: neurologic damage 3.0 10 
cardiac arrest. The others are well, although 
not all have perfect liver function. The eight 
survivors are being treated with 8 12 mg/ 
kg/day of cyclosporin-A plus 10-25 mg/day 
of prednisone. 
We mentioned earlier our conclusions 
about the optimal way to use cyclosporin-A in 
kidney graft recipients. It was not surprising 
that these conclusions seemed to apply in liver 
transplantation. Five of the eight patients who 
survived operation were suspected of having 
rejection within 1-4 months postoperatively. 
In two cases there were increases in serum 
transaminases and alkaline phosphatase, but 
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Fig. 4. The development of 
uremia in an orthotopic liver 
recipient treated with cyclo-
sporin-A. Kidney function re-
turned to normal after a reduc-
tion in cyclosporin-A dose. 
Note that prednisone was 
given from the beginning. but 
in rapidly decreasing amounts. 
Later (not shown). the penalty 
of decreasing immunosuppres-
sion was liver homograft rejec-
tion as judged by liver biopsy. 
An increase of the cyclospo-
rin-A dose plus steroid therapy 
seemed to control the rejec-
tion. but subsequently it was 
found that the liver homograft 
was partly constructed. The 
cholecystojejunostomy was 
converted to a choledochojeju-
nostomy. with amelioration of 
the low-grade jaundice. 
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no jaundice. Three other patients also had 
increases in serum bilirubin. 
One to five liver biopsies were obtained in 
these five patients. In every case the grafts 
contained mononuclear cells and other find-
ings compatible with cellular rejection. Eosin-
ophiles were more prominent than in rejecting 
livers under conventional immunosuppres-
sion. The liver function abnormalities were 
promptly ameliorated with steroid therapy, 
thus reinforcing the histopathologic impres-
sion of rejection. 
The high incidence of rejection in liver 
recipients treated with cyclosporin-A but not 
initially given prednisone has caused us to 
adopt the same policy of prophylactic steroid 
immunosuppression (Fig. 4) described earlier 
for adult renal graft recipients, namely, 200 
mg prednisone on the first postoperative day, 
reduction by decrements of 40 mg/day until 
40 mg is reached. On the next day, the main-
tenance dose of 20 mg is reached from which 
further slow reductions (or increases) are 
individualized (Fig. 4). The development of 
rejection in spite of such treatment signals a 
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need for more steroids. We do not respond by 
drastically increasing doses of cyclosporin-A, 
since we have learned from kidney graft 
recipients that the hepatotoxicity range is 
entered with daily doses of 15-20 mg/kg. 
Furthermore, nephrotoxicity could be the 
price of such adjustments. Three of our eight 
liver recipients under cyclosporin-A have 
developed renal dysfunction, which promptly 
improved after a dose reduction (Fig. 4). 
SUMMARY 
The field of liver transplantation, which 
had reached a state of tantalizing but incom-
pletely fulfilled promise, has been revitalized 
by experience with the new immunosuppres-
sive drug, cyclosporin-A. For optimal value, 
cyclosporin-A in both kidney and liver recip-
ients has required steroid therapy, but the 
amounts of prednisone have been a small 
fraction of those used in the past. It seems to 
us that the cyclosporin-A-prednisone combi-
nation should permit a new chapter to be 
opened in transplantation. 
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